Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Findings
What do systematic reviews say?
45 questions · 45 findings · 3 reviews · Cystic Fibrosis and Genetic Disorders
No studies found 7 · 15.6%GRADE not reported 0 · 0%Very low 15 · 33.3%Low 18 · 40%Moderate 5 · 11.1%High 0 · 0%
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted123 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ change from baseline in CFCS total score and CFQ‐R respiratory domain · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted391 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1 study · 391 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 324 participantsLow
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ Inhaled mannitol vs dornase alfa
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEV1 mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 2.8231 participantsVery low